Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

A microRNA atlas of the human prefrontal cortex across the adult lifespan.

bioRxiv : the preprint server for biology·2026
Same author

Engineering Brain Injury In Vitro: Human iPSC-Based Organoids in Microfluidic Systems.

Applied sciences (Basel, Switzerland)·2026
Same author

iS2C2: a cointelligent platform for mechanistic discovery of disease cellular crosstalk.

Signal transduction and targeted therapy·2026
Same author

Recapitulation of plaque formation, tau pathology, and neurodegeneration in a human 3D matrix model of Alzheimer's disease.

Cell reports methods·2026
Same author

Innate Immune Evasion of Lyme Disease Pathogen Drives Alzheimer-Like Pathology.

Research square·2026
Same author

Recapitulating Alzheimer's disease pathophysiology with a microfluidic neurospheroid-grafted endothelial barrier model.

Molecular brain·2026

関連する実験動画

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

創薬

Pourya Naderi Yeganeh1,2, Sang Su Kwak2,3, Mehdi Jorfi2,3

  • 1Beth Israel Deaconess Medical Center, Boston, MA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
まとめ
この要約は機械生成です。

新しいバイオインフォマティクスプラットフォームである統合経路活性解析（IPAA）は、ヒトに関連するアルツハイマー病（AD）のメカニズムを正確に予測する。モデルにおけるp38 MAPK-MK2経路を標的とするとAD病理が減少し、有望な治療戦略を提供する。

キーワード:
アルツハイマー病創薬バイオインフォマティクスp38 MAPK-MK2経路神経科学薬理学

さらに関連する動画

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

関連する実験動画

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

科学分野:

  • 神経科学
  • バイオインフォマティクス
  • 薬理学

背景:

  • アルツハイマー病（AD）の治療法は、前臨床モデルでは成功しても、ヒトの臨床試験では失敗することが多い。
  • ヒト治療への関連性を評価するために、前臨床標的メカニズムを検証するための体系的なアプローチが必要である。
  • 臨床前のギャップを埋めることは、効果的なAD創薬に不可欠である。

研究 の 目的:

  • 前臨床モデルのヒトADへの関連性を評価するためのバイオインフォマティクスプラットフォーム（IPAA）を開発および検証する。
  • ヒト脳と前臨床モデルの間で保存されたAD経路の調節不全を特定する。
  • 特定された経路をADモデルで標的とすることの治療可能性を評価する。

主な方法:

  • オミクスデータから経路活性をマッピングするために統合経路活性解析（IPAA）を開発した。
  • ヒトAD細胞モデルとAD脳のトランスクリプトームのメカニズム類似性を評価した。
  • リン酸化プロテオミクスを実施し、3Dモデルで主要な経路を薬理学的にテストした。

主要な成果:

  • IPAAは、AD脳領域間の経路調節不全の高い相関（r=0.84）を示した。
  • AD脳と3Dモデルの間で、p38 MAPK、YAP1/TAZ、E-cadherin、CDC20、APC/Cを含む83の共有調節不全経路を特定した。
  • p38 MAPKをロスマピモドで標的とすると、3DモデルとヒトミクログリアにおけるAD病理マーカーが大幅に減少し、p38 MAPK-MK2軸の役割が強調された。

結論:

  • IPAAは、AD病理に対する標的経路の前臨床評価を迅速化する。
  • p38 MAPK-MK2軸は、ヒトAD病理の重要なドライバーである。
  • このアプローチは、ADに対する臨床的影響の可能性のある経路を標的とすることへの信頼を高める。